Sagimet Biosciences Inc. 近日宣布，已收到美国食品药品监督管理局（FDA）的“研究可继续进行”函件，并获得了新药临床试验（IND）许可。这标志着该公司针对青少年及成人痤疮的III期临床试验，已获准正式启动。这一进展，无疑为这家生物科技公司的研发管线注入了强心剂。
Sagimet Biosciences Inc. 近日宣布，已收到美国食品药品监督管理局（FDA）的“研究可继续进行”函件，并获得了新药临床试验（IND）许可。这标志着该公司针对青少年及成人痤疮的III期临床试验，已获准正式启动。这一进展，无疑为这家生物科技公司的研发管线注入了强心剂。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.